CA2803027A1 - Treatment of proliferative diseases - Google Patents

Info

Publication number

CA2803027A1

CA2803027A1 CA2803027A CA2803027A CA2803027A1 CA 2803027 A1 CA2803027 A1 CA 2803027A1 CA 2803027 A CA2803027 A CA 2803027A CA 2803027 A CA2803027 A CA 2803027A CA 2803027 A1 CA2803027 A1 CA 2803027A1

Authority

CA

Canada

Prior art keywords

seq

cancer

nucleic acid

plant defensin

nad1

Prior art date

2010-06-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 201000010099 disease Diseases 0.000 title claims abstract description 55
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 55
• 230000002062 proliferating effect Effects 0.000 title claims abstract description 46
• 238000011282 treatment Methods 0.000 title abstract description 27
• 108010002069 Defensins Proteins 0.000 claims abstract description 283
• 102000000541 Defensins Human genes 0.000 claims abstract description 283
• 238000000034 method Methods 0.000 claims abstract description 66
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
• 201000011510 cancer Diseases 0.000 claims abstract description 25
• 210000004027 cell Anatomy 0.000 claims description 221
• 101000883593 Nicotiana alata Flower-specific defensin Proteins 0.000 claims description 191
• 241000196324 Embryophyta Species 0.000 claims description 176
• 150000007523 nucleic acids Chemical class 0.000 claims description 97
• 108020004707 nucleic acids Proteins 0.000 claims description 72
• 102000039446 nucleic acids Human genes 0.000 claims description 72
• 210000004881 tumor cell Anatomy 0.000 claims description 65
• 239000013598 vector Substances 0.000 claims description 50
• 239000012634 fragment Substances 0.000 claims description 32
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
• 230000002829 reductive effect Effects 0.000 claims description 24
• 101100100081 Oryza sativa subsp. japonica TPP3 gene Proteins 0.000 claims description 23
• 201000001441 melanoma Diseases 0.000 claims description 22
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
• 230000002949 hemolytic effect Effects 0.000 claims description 19
• 239000008194 pharmaceutical composition Substances 0.000 claims description 18
• 244000061322 Nicotiana alata Species 0.000 claims description 14
• 206010060862 Prostate cancer Diseases 0.000 claims description 11
• 239000003085 diluting agent Substances 0.000 claims description 11
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
• 231100000135 cytotoxicity Toxicity 0.000 claims description 10
• 210000004962 mammalian cell Anatomy 0.000 claims description 10
• 240000007377 Petunia x hybrida Species 0.000 claims description 9
• 206010006187 Breast cancer Diseases 0.000 claims description 8
• 208000026310 Breast neoplasm Diseases 0.000 claims description 8
• 241001144480 Nicotiana suaveolens Species 0.000 claims description 8
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
• 240000003768 Solanum lycopersicum Species 0.000 claims description 8
• 230000000295 complement effect Effects 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 206010025323 Lymphomas Diseases 0.000 claims description 7
• 235000002560 Solanum lycopersicum Nutrition 0.000 claims description 7
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 7
• 230000003013 cytotoxicity Effects 0.000 claims description 7
• 239000003814 drug Substances 0.000 claims description 7
• 201000002313 intestinal cancer Diseases 0.000 claims description 6
• 208000032839 leukemia Diseases 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
• 206010005949 Bone cancer Diseases 0.000 claims description 5
• 208000018084 Bone neoplasm Diseases 0.000 claims description 5
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 5
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
• 206010033128 Ovarian cancer Diseases 0.000 claims description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
• 201000010881 cervical cancer Diseases 0.000 claims description 5
• 201000007270 liver cancer Diseases 0.000 claims description 5
• 208000014018 liver neoplasm Diseases 0.000 claims description 5
• 201000005202 lung cancer Diseases 0.000 claims description 5
• 208000020816 lung neoplasm Diseases 0.000 claims description 5
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
• 201000002528 pancreatic cancer Diseases 0.000 claims description 5
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
• 238000002360 preparation method Methods 0.000 claims description 5
• 238000012216 screening Methods 0.000 claims description 5
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
• 201000002510 thyroid cancer Diseases 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 235000002634 Solanum Nutrition 0.000 claims description 2
• 241000207763 Solanum Species 0.000 claims description 2
• 235000002262 Lycopersicon Nutrition 0.000 claims 1
• 241000227653 Lycopersicon Species 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 54
• 230000002265 prevention Effects 0.000 abstract description 4
• 235000018102 proteins Nutrition 0.000 description 87
• 108090000623 proteins and genes Proteins 0.000 description 87
• 102000004169 proteins and genes Human genes 0.000 description 87
• 230000000694 effects Effects 0.000 description 60
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 41
• 150000002632 lipids Chemical class 0.000 description 34
• 230000027455 binding Effects 0.000 description 33
• 210000003743 erythrocyte Anatomy 0.000 description 33
• 101100459440 Caenorhabditis elegans nac-3 gene Proteins 0.000 description 30
• 230000001965 increasing effect Effects 0.000 description 29
• 108090000765 processed proteins & peptides Proteins 0.000 description 29
• 239000002953 phosphate buffered saline Substances 0.000 description 28
• 239000000047 product Substances 0.000 description 28
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 27
• 102000004196 processed proteins & peptides Human genes 0.000 description 25
• 210000002966 serum Anatomy 0.000 description 25
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
• 235000001014 amino acid Nutrition 0.000 description 22
• 229920001184 polypeptide Polymers 0.000 description 22
• 150000001413 amino acids Chemical class 0.000 description 21
• 241000699670 Mus sp. Species 0.000 description 20
• 241000894007 species Species 0.000 description 20
• 238000000684 flow cytometry Methods 0.000 description 19
• 230000009089 cytolysis Effects 0.000 description 16
• 230000001413 cellular effect Effects 0.000 description 15
• 239000002773 nucleotide Substances 0.000 description 15
• 125000003729 nucleotide group Chemical group 0.000 description 15
• 230000037396 body weight Effects 0.000 description 14
• 238000003556 assay Methods 0.000 description 13
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 13
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• 238000002835 absorbance Methods 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 239000012528 membrane Substances 0.000 description 12
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
• 241000208292 Solanaceae Species 0.000 description 11
• 238000001514 detection method Methods 0.000 description 11
• 238000004007 reversed phase HPLC Methods 0.000 description 11
• 230000035899 viability Effects 0.000 description 11
• 241000238631 Hexapoda Species 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 238000013459 approach Methods 0.000 description 10
• 229940098773 bovine serum albumin Drugs 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• -1 phosphatidyl alanine Chemical compound 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 241000283973 Oryctolagus cuniculus Species 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 238000009396 hybridization Methods 0.000 description 9
• 150000003904 phospholipids Chemical class 0.000 description 9
• 239000002243 precursor Substances 0.000 description 9
• 241000235058 Komagataella pastoris Species 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 229920002684 Sepharose Polymers 0.000 description 8
• 230000001028 anti-proliverative effect Effects 0.000 description 8
• 239000002246 antineoplastic agent Substances 0.000 description 8
• 238000005119 centrifugation Methods 0.000 description 8
• 230000004576 lipid-binding Effects 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 108091033319 polynucleotide Proteins 0.000 description 8
• 102000040430 polynucleotide Human genes 0.000 description 8
• 239000002157 polynucleotide Substances 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 7
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 230000003833 cell viability Effects 0.000 description 7
• 238000003570 cell viability assay Methods 0.000 description 7
• 235000018417 cysteine Nutrition 0.000 description 7
• 239000000523 sample Substances 0.000 description 7
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 241000283074 Equus asinus Species 0.000 description 6
• 241000233866 Fungi Species 0.000 description 6
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
• 108060001084 Luciferase Proteins 0.000 description 6
• 239000005089 Luciferase Substances 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
• ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 6
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 6
• 230000000845 anti-microbial effect Effects 0.000 description 6
• 229910002092 carbon dioxide Inorganic materials 0.000 description 6
• 210000000170 cell membrane Anatomy 0.000 description 6
• 239000000470 constituent Substances 0.000 description 6
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
• 238000000326 densiometry Methods 0.000 description 6
• 238000003119 immunoblot Methods 0.000 description 6
• 239000012064 sodium phosphate buffer Substances 0.000 description 6
• 238000002798 spectrophotometry method Methods 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 101000918874 Gymnadenia conopsea Defensin-like protein Proteins 0.000 description 5
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
• 235000004279 alanine Nutrition 0.000 description 5
• 230000000843 anti-fungal effect Effects 0.000 description 5
• 230000029918 bioluminescence Effects 0.000 description 5
• 238000005415 bioluminescence Methods 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 150000001875 compounds Chemical class 0.000 description 5
• 239000003636 conditioned culture medium Substances 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
• 238000003752 polymerase chain reaction Methods 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 108091035707 Consensus sequence Proteins 0.000 description 4
• 101000918971 Papio hamadryas Defensin-1 Proteins 0.000 description 4
• 101000918969 Petunia hybrida Floral defensin-like protein 1 Proteins 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 206010039491 Sarcoma Diseases 0.000 description 4
• 239000012298 atmosphere Substances 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 244000309466 calf Species 0.000 description 4
• 238000002648 combination therapy Methods 0.000 description 4
• 230000001472 cytotoxic effect Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000001378 electrochemiluminescence detection Methods 0.000 description 4
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 239000013604 expression vector Substances 0.000 description 4
• 239000012997 ficoll-paque Substances 0.000 description 4
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
• 229910052737 gold Inorganic materials 0.000 description 4
• 239000010931 gold Substances 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 208000025113 myeloid leukemia Diseases 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 150000003906 phosphoinositides Chemical class 0.000 description 4
• 229920001296 polysiloxane Polymers 0.000 description 4
• 239000008057 potassium phosphate buffer Substances 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 230000000717 retained effect Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 238000004626 scanning electron microscopy Methods 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• 241000208125 Nicotiana Species 0.000 description 3
• 108091005461 Nucleic proteins Proteins 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 235000002595 Solanum tuberosum Nutrition 0.000 description 3
• 244000061456 Solanum tuberosum Species 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 230000006037 cell lysis Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 210000004351 coronary vessel Anatomy 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 239000010432 diamond Substances 0.000 description 3
• 239000012153 distilled water Substances 0.000 description 3
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 230000002900 effect on cell Effects 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 201000005962 mycosis fungoides Diseases 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 201000001514 prostate carcinoma Diseases 0.000 description 3
• 239000012460 protein solution Substances 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 239000008279 sol Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 230000036962 time dependent Effects 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 2
• 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 2
• 240000003291 Armoracia rusticana Species 0.000 description 2
• 235000011330 Armoracia rusticana Nutrition 0.000 description 2
• 241000351920 Aspergillus nidulans Species 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 102100026887 Beta-defensin 103 Human genes 0.000 description 2
• 206010004593 Bile duct cancer Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 108060002063 Cyclotide Proteins 0.000 description 2
• 206010011732 Cyst Diseases 0.000 description 2
• 241000157286 Dahlia merckii Species 0.000 description 2
• 101710157752 Defensin-like protein Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 241000223218 Fusarium Species 0.000 description 2
• 241000223221 Fusarium oxysporum Species 0.000 description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 239000004471 Glycine Chemical group 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 235000007340 Hordeum vulgare Nutrition 0.000 description 2
• 240000005979 Hordeum vulgare Species 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 241000228457 Leptosphaeria maculans Species 0.000 description 2
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
• 231100000002 MTT assay Toxicity 0.000 description 2
• 238000000134 MTT assay Methods 0.000 description 2
• 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241001608711 Melo Species 0.000 description 2
• 208000003445 Mouth Neoplasms Diseases 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 101000722180 Petunia hybrida Floral defensin-like protein 2 Proteins 0.000 description 2
• 241000235648 Pichia Species 0.000 description 2
• 108010064851 Plant Proteins Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 201000000582 Retinoblastoma Diseases 0.000 description 2
• 241000239226 Scorpiones Species 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 108010076830 Thionins Proteins 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000007244 Zea mays Nutrition 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 229930013930 alkaloid Natural products 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 101150059062 apln gene Proteins 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 239000001569 carbon dioxide Substances 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 210000004534 cecum Anatomy 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 208000006990 cholangiocarcinoma Diseases 0.000 description 2
• 238000002983 circular dichroism Methods 0.000 description 2
• 238000001142 circular dichroism spectrum Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 208000031513 cyst Diseases 0.000 description 2
• 150000001945 cysteines Chemical class 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 230000018044 dehydration Effects 0.000 description 2
• 238000006297 dehydration reaction Methods 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 210000001198 duodenum Anatomy 0.000 description 2
• 235000013399 edible fruits Nutrition 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 230000028644 hyphal growth Effects 0.000 description 2
• 230000002267 hypothalamic effect Effects 0.000 description 2
• 210000003405 ileum Anatomy 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 238000007654 immersion Methods 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 210000001630 jejunum Anatomy 0.000 description 2
• 238000007834 ligase chain reaction Methods 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 230000000921 morphogenic effect Effects 0.000 description 2
• 230000000877 morphologic effect Effects 0.000 description 2
• 230000004660 morphological change Effects 0.000 description 2
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 235000021118 plant-derived protein Nutrition 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 230000036515 potency Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 229960005267 tositumomab Drugs 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 210000003606 umbilical vein Anatomy 0.000 description 2
• 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 2
• 208000037965 uterine sarcoma Diseases 0.000 description 2
• BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• ZCWPHDXKEDBCER-UHFFFAOYSA-N 2,5-diphenyl-2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=CC=CC=C1C1=[NH+]N(C=2C=CC=CC=2)N=N1 ZCWPHDXKEDBCER-UHFFFAOYSA-N 0.000 description 1
• FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
• 230000005730 ADP ribosylation Effects 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 101710083587 Antifungal protein Proteins 0.000 description 1
• 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
• 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 241001610441 Arabidopsis halleri Species 0.000 description 1
• 235000003911 Arachis Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 241000235349 Ascomycota Species 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 241000208838 Asteraceae Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 238000000035 BCA protein assay Methods 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000031638 Body Weight Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 241001313742 Callosobruchus chinensis Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 235000002566 Capsicum Nutrition 0.000 description 1
• 235000002567 Capsicum annuum Nutrition 0.000 description 1
• 240000004160 Capsicum annuum Species 0.000 description 1
• 235000018306 Capsicum chinense Nutrition 0.000 description 1
• 244000185501 Capsicum chinense Species 0.000 description 1
• 240000008574 Capsicum frutescens Species 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
• 206010007281 Carcinoid tumour of the stomach Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 238000011537 Coomassie blue staining Methods 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 108010069514 Cyclic Peptides Proteins 0.000 description 1
• 102000001189 Cyclic Peptides Human genes 0.000 description 1
• 102000011376 Cyclin-like Human genes 0.000 description 1
• 108050001682 Cyclin-like Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 241000132500 Dahlia <angiosperm> Species 0.000 description 1
• 235000012040 Dahlia pinnata Nutrition 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• 101710085715 Defensin-like protein 2 Proteins 0.000 description 1
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
• 101710164770 Drosomycin Proteins 0.000 description 1
• 241000255601 Drosophila melanogaster Species 0.000 description 1
• 101100010343 Drosophila melanogaster lobo gene Proteins 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 235000014066 European mistletoe Nutrition 0.000 description 1
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
• 108010040476 FITC-annexin A5 Proteins 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 241000223194 Fusarium culmorum Species 0.000 description 1
• 241000223195 Fusarium graminearum Species 0.000 description 1
• 241000879806 Fusarium oxysporum f. sp. vasinfectum Species 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 206010061988 Gestational trophoblastic tumour Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 244000020551 Helianthus annuus Species 0.000 description 1
• 235000003222 Helianthus annuus Nutrition 0.000 description 1
• 101800002189 Hevein Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 241001495448 Impatiens <genus> Species 0.000 description 1
• 240000000917 Impatiens balsamina Species 0.000 description 1
• 235000015912 Impatiens biflora Nutrition 0.000 description 1
• 206010061217 Infestation Diseases 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 241000208467 Macadamia Species 0.000 description 1
• 240000007575 Macadamia integrifolia Species 0.000 description 1
• 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 240000004658 Medicago sativa Species 0.000 description 1
• 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 101000957678 Mus musculus Cytochrome P450 7B1 Proteins 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 206010028729 Nasal cavity cancer Diseases 0.000 description 1
• 206010028767 Nasal sinus cancer Diseases 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 241000221961 Neurospora crassa Species 0.000 description 1
• 101100226116 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) esa-1 gene Proteins 0.000 description 1
• 241000862464 Nicotiana excelsior Species 0.000 description 1
• 241000876839 Nicotiana paniculata Species 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 231100000322 OECD 423 Acute Oral toxicity - Acute Toxic Class Method Toxicity 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241001508464 Orobanche Species 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 241000025414 Pentalagus furnessi Species 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• 241000975369 Phoma betae Species 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010035052 Pineal germinoma Diseases 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 241000209504 Poaceae Species 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 244000088415 Raphanus sativus Species 0.000 description 1
• 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
• 101000957679 Rattus norvegicus 25-hydroxycholesterol 7-alpha-hydroxylase Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 244000152640 Rhipsalis cassutha Species 0.000 description 1
• 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241001107098 Rubiaceae Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 1
• 241000221662 Sclerotinia Species 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 101710187074 Serine proteinase inhibitor Proteins 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 101150057615 Syn gene Proteins 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 241000561282 Thielaviopsis basicola Species 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 240000007026 Tylosema esculentum Species 0.000 description 1
• 240000006064 Urena lobata Species 0.000 description 1
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
• 206010046392 Ureteric cancer Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 241001123668 Verticillium dahliae Species 0.000 description 1
• 240000004922 Vigna radiata Species 0.000 description 1
• 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
• 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241001106476 Violaceae Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 108010006886 Vitrogen Proteins 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 229960001445 alitretinoin Drugs 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229940126675 alternative medicines Drugs 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 229940025131 amylases Drugs 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000036436 anti-hiv Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 235000021405 artificial diet Nutrition 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229960002938 bexarotene Drugs 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 239000007469 bmm - medium Substances 0.000 description 1
• 201000008873 bone osteosarcoma Diseases 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 239000001511 capsicum annuum Substances 0.000 description 1
• 239000001390 capsicum minimum Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 239000003093 cationic surfactant Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 238000003654 cell permeability assay Methods 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 208000030239 cerebral astrocytoma Diseases 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 238000009614 chemical analysis method Methods 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 238000009108 consolidation therapy Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• UXGKDCRTOGQACC-YMWYTIKZSA-N cyclotide kalata b1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N2)[C@H](C)O)NC(=O)CNC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC3=O)[C@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](C)O)C(=O)N4)C(C)C)CCN1C(=O)[C@H](CC(C)C)NC(=O)CNNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC=5C6=CC=CC=C6NC=5)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H]4C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H]([C@H](C)O)C(=O)N[C@H]3CSSC1 UXGKDCRTOGQACC-YMWYTIKZSA-N 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 108010017271 denileukin diftitox Proteins 0.000 description 1
• 229960002923 denileukin diftitox Drugs 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 229910003460 diamond Inorganic materials 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000021004 dietary regimen Nutrition 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• 102000038379 digestive enzymes Human genes 0.000 description 1
• 108091007734 digestive enzymes Proteins 0.000 description 1
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000006353 environmental stress Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229940093476 ethylene glycol Drugs 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960000752 etoposide phosphate Drugs 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 210000002468 fat body Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000000349 field-emission scanning electron micrograph Methods 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 230000008124 floral development Effects 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 244000053095 fungal pathogen Species 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• 230000009422 growth inhibiting effect Effects 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000010235 heart cancer Diseases 0.000 description 1
• 208000024348 heart neoplasm Diseases 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 210000000087 hemolymph Anatomy 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• WKMZPSWMEXVKKG-XITFREQTSA-N hevein Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CS)C(=O)NCC(=O)OC(=O)CC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CNC2=CC=CC=C12 WKMZPSWMEXVKKG-XITFREQTSA-N 0.000 description 1
• 208000029824 high grade glioma Diseases 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 230000007236 host immunity Effects 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 229930190166 impatien Natural products 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 239000011147 inorganic material Substances 0.000 description 1
• 108010078480 insect defensin A Proteins 0.000 description 1
• 230000000749 insecticidal effect Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 229960004592 isopropanol Drugs 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 108010053156 lipid transfer protein Proteins 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 201000011614 malignant glioma Diseases 0.000 description 1
• 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000000716 merkel cell Anatomy 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 229960002900 methylcellulose Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000004570 mortar (masonry) Substances 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 208000022982 optic pathway glioma Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 231100000204 oral acute (single dose) toxicity testing Toxicity 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 201000007052 paranasal sinus cancer Diseases 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000001935 permeabilising effect Effects 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 238000000554 physical therapy Methods 0.000 description 1
• 201000007315 pineal gland astrocytoma Diseases 0.000 description 1
• 201000004838 pineal region germinoma Diseases 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229960001237 podophyllotoxin Drugs 0.000 description 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
• YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
• 229960000214 pralatrexate Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• 229960003452 romidepsin Drugs 0.000 description 1
• 108010091666 romidepsin Proteins 0.000 description 1
• OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 239000003001 serine protease inhibitor Substances 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229920002545 silicone oil Polymers 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 229940032094 squalane Drugs 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 208000037969 squamous neck cancer Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229960000235 temsirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 150000003505 terpenes Chemical class 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 108010034266 theta-defensin Proteins 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000001573 trophoblastic effect Effects 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 239000012137 tryptone Substances 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 229910021642 ultra pure water Inorganic materials 0.000 description 1
• 239000012498 ultrapure water Substances 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 201000011294 ureter cancer Diseases 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 231100000747 viability assay Toxicity 0.000 description 1
• 238000003026 viability measurement method Methods 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 210000000239 visual pathway Anatomy 0.000 description 1
• 230000004400 visual pathway Effects 0.000 description 1
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1